Post-myocardial infarction beta-blocker therapy: the bradycardia conundrum. Rationale and design for the Pacemaker & beta-blocker therapy post-MI (PACE-MI) trial.
Post-myocardial infarction beta-blocker therapy: the bradycardia conundrum. Rationale and design for the Pacemaker & beta-blocker therapy post-MI (PACE-MI) trial.
复制标题
心肌梗塞后β受体阻滞剂治疗：心动过缓难题。
DOI：
10.1016/j.ahj.2007.10.041
复制
发表时间：
2008
影响因子：
4.8
通讯作者：
Smith,Sidney
中科院分区：
文献类型：
--
作者：
Goldberger,JeffreyJ;Bonow,RobertO;Cuffe,Michael;Dyer,Alan;Greenland,Philip;Rosenberg,Yves;O'Rourke,Robert;Shah,PredimanK;Smith,Sidney
Multiple clinical trials have demonstrated β-blockers improving survival after myocardial infarction (MI). Patients with “bradycardia-related” contraindications to β-blockers, such as those with asymptomatic bradycardia or AV conduction abnormalities, have been excluded from clinical trials of β-blockers and continue to be excluded from post-MI β-blocker therapy in routine clinical practice. These patients tend to be elderly and have a high 1-year mortality. If β-blockers provide benefit to the post-MI patient independent of their heart rate–lowering effect, then these patients could benefit substantially from initiation of β-blocker therapy. However, in this particular group of patients, β-blockers can be safely initiated only if more severe or significant bradycardia can be prevented by pacemaker implantation. It is unclear whether adverse effects related to pacemaker implantation could also negate some or all of the hypothesized benefit of β-blocker therapy. Although β-blockers are particularly effective in the elderly, the benefit of β-blocker therapy in patients with bradycardia-related contraindications to β-blockers has not been established. The Pacing Clin Electrophysiol-MI trial is a randomized controlled trial that will address whether β-blocker therapy enabled by pacemaker implantation is superior to no β-blocker and no pacemaker therapy after MI in patients with rhythm contraindications to β-blockers or in those who have developed symptomatic bradycardia due to β-blockers. The trial will randomize 1124 patients to standard therapy (not to include β-blockers as patients must have a contraindication to be enrolled) or standard therapy plus pacemaker implantation and β-blocker. The primary end point is the composite end point of total mortality plus nonfatal reinfarction.
登录
查看更多内容
患有冠状动脉疾病的绝经后妇女的雌激素替代疗法和运动表现。
DOI：
10.1016/s0002-9149(96)00685-6
发表时间：
1997
期刊：
The American journal of cardiology
影响因子：
--
作者：
E. Sbarouni;Z. Kyriakides;N. Nikolaou;D. Kremastinos
通讯作者：
D. Kremastinos
十个国家人群急性心肌梗死的治疗模式
影响因子：
2.9
作者：
F. Venturini;M. Romero;G. Tognoni
通讯作者：
G. Tognoni
β-肾上腺素能阻滞药物对实验性心室颤动阈值的比较影响。
DOI：
10.1016/0002-9149(83)90368-5
发表时间：
1983
期刊：
The American journal of cardiology
影响因子：
--
作者：
Anderson,JL;Rodier,HE;Green,LS
通讯作者：
Green,LS
溶栓时代老年患者急性心肌梗死的治疗和结局
影响因子：
6.3
作者：
N. Mahon;M. Codd;Cliona O'Rorke;Bernadette Egan;H. McCann;D. Sugrue
通讯作者：
D. Sugrue
影响因子：
2.8
作者：
Aronow, WS;Ahn, C;Kronzon, I
通讯作者：
Kronzon, I